FLASHBACK: Former FDA Commissioner Scott Gottlieb joins Pfizer’s board of directors

Jun 27 2019

(Angelica LaVito, CNBC) Scott Gottlieb, who stepped down as Food and Drug Administration Commissioner in April, will join Pfizer’s board of directors, the company announced Thursday.

Gottlieb resigned from the FDA this spring after nearly two years at the helm. During his tenure, Gottlieb advanced a number of prescription drug policies, including to push the FDA to speed up generic drug approvals and use its powers to encourage wider use of biosimilars, or copycat versions of complex and often costly biologic drugs.

Biosimilar manufacturers, including Pfizer, have complained about roadblocks stalling biosimilars from becoming widely used. Having Gottlieb to advise the company could help Pfizer, one of the largest biopharmaceutical companies, navigate the landscape

In a tweet, Gottlieb said he’s “honored” to join the board “to promote medical innovation, advance patient care, and secure access to better healthcare outcomes for families around the world.”

CEO Albert Bourla, who succeeded Ian Read on January 1, shuffled the company’s senior management team last year and is leading the effort to restructure the pharmaceutical giant into a more nimble company. Pfizer announced plans last July to reorganize into three units, separating out its consumer healthcare business that it had been trying to sell.

“We are fortunate to have Dr. Gottlieb join Pfizer’s Board of Directors,” Pfizer Executive Chairman and former CEO Ian Read said in a statement. “Scott’s expertise in health care, public policy and the industry will be an asset to our company and enable our shareholders to continue to benefit from a Board representing a balance of experience, competencies and perspectives.”

Since leaving the FDA, Gottlieb has returned to the American Enterprise Institute as a resident fellow and as a special partner at venture capital firm New Enterprise Associates, where he worked before joining the FDA. He also joined CNBC as a contributor.

Disclosure: Scott Gottlieb is a CNBC contributor.
CNBC’s Berkeley Lovelace Jr. contributed to this report.

Comment: This is just one example of why the FDA, WHO, CDC are collinear with the BigPharma criminals. They don’t work to help people or to promote proper fact-based science and make better and more affordable drugs. They work together on their aggressive agenda to make money and gain power and control over people’s lives.We can now clearly see one of the reasons why they are still keeping alive the false Corona pandemic and aggressively pushing mandatory vaccination. They are business partners working and helping each other to fulfill their business plans.

Notify of
Inline Feedbacks
View all comments